Tarek Abdelmoneim Abdelaziz , Randa Hussiny Mohammad , Marwa Mohammed Gad , Mohamed Gamel ‎Fawzy Ghareeb‎

Abstract

Background: Intracoronary stent restenosis (ISR) is a famous catastrophe, always following percutaneous coronary interventions (PCI). Many investigations were performed to avoid this complication by the addition of many cytotoxic drugs to stent platform for prevention of neo-intimal hyperplasia and smooth muscle cell proliferation, or by finding a protective drug against this problem, such as dual antiplatelet therapy. Our research was conducted to detect the protective drugs against the risk of intracoronary stent restenosis among all drugs of medical treatment for ischemic heart diseases. Results: The study reported that 54, 26, 54, and 34% of patients respectively administrated by clopidogrel, nitrates, angiotensin-converting enzyme inhibitors (ACEI) and statins developed ISR after PCI when compared to the other group of patients who did not develop ISR. So, these drugs were protective against the risk of ISR (P value<0.001). We also reported that 74, 4, and 90% of patients administrated respectively by aspirin, warfarin, beta-1 blockers (BB) developed ISR after PCI when compared to the other group of patients who did not develop ISR. So, there was no association between these drugs and risk of ISR (P value>0.05). Conclusions: This study concluded that clopidogrel, nitrates, ACEI, and statins are protective drugs against the risk of ISR complications after PCI procedures‎.

Citation Formats: